MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
MicroRNAs comprise a broad class of small non-coding RNAs that control expression of complementary target messenger RNAs. Dysregulation of microRNAs by several mechanisms has been described in various disease states including cardiac disease. Whereas previous studies of cardiac disease have focused on microRNAs that are primarily expressed in cardiomyocytes, the role of microRNAs expressed in other cell types of the heart is unclear. Here we show that microRNA-21 (miR-21, also known as Mirn21) regulates the ERK-MAP kinase signalling pathway in cardiac fibroblasts, which has impacts on global cardiac structure and function. miR-21 levels are increased selectively in fibroblasts of the failing heart, augmenting ERK-MAP kinase activity through inhibition of sprouty homologue 1 (Spry1). This mechanism regulates fibroblast survival and growth factor secretion, apparently controlling the extent of interstitial fibrosis and cardiac hypertrophy. In vivo silencing of miR-21 by a specific antagomir in a mouse pressure-overload-induced disease model reduces cardiac ERK-MAP kinase activity, inhibits interstitial fibrosis and attenuates cardiac dysfunction. These findings reveal that microRNAs can contribute to myocardial disease by an effect in cardiac fibroblasts. Our results validate miR-21 as a disease target in heart failure and establish the therapeutic efficacy of microRNA therapeutic intervention in a cardiovascular disease setting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epigenetic manipulation through long non-coding RNAs, miRNA modulators, and other oligonucleotides has yielded promising outcomes in experimental settings.162–165”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [162]
Citations
Cites
1 retracted
Rockman, H. A., Ross, R. S., Harris, A. N., Knowlton, K. U., Steinhelper, M. E., Field, L. J., Ross, J., & Chien, K. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.8277 · Cited by 797
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Self-citationA microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., & Saltiel, A. R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7686 · Cited by 2,679
MicroRNA-133 controls cardiac hypertrophy
Carè, A., Catalucci, D., Felicetti, F., Bonci, D., Addario, A., Gallo, P., Bang, M.-L., Segnalini, P., Gu, Y., Dalton, N. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1582 · Cited by 1,776
Control of Stress-Dependent Cardiac Growth and Gene Expression by a MicroRNA
van Rooij, E., Sutherland, L. B., Qi, X., Richardson, J. A., Hill, J., & Olson, E. N. (2007) · Science · doi:10.1126/science.1139089 · Cited by 1,657
Dysregulation of Cardiogenesis, Cardiac Conduction, and Cell Cycle in Mice Lacking miRNA-1-2
Zhao, Y., Ransom, J. F., Li, A., Vedantham, V., von Drehle, M., Muth, A. N., Tsuchihashi, T., McManus, M. T., Schwartz, R. J., & Srivastava, D. (2007) · Cell · doi:10.1016/j.cell.2007.03.030 · Cited by 1,429
Yang, B., Lin, H., Xiao, J., Lu, Y., Luo, X., Li, B., Zhang, Y., Xu, C., Bai, Y., Wang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1569 · Cited by 1,138
Cited by
Non-coding RNAs in human disease
Esteller, M. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3074 · Cited by 4,825
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
“For example, miR-21 is expressed in the lungs of individuals with IPF, and mice treated with miR-21 antisense probes were protected from bleomycin-induced pulmonary fibrosis 138 and cardiac fibrosis induced by pressure overload 139 .”
Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches
Beermann, J., Piccoli, M.-T., Viereck, J., & Thum, T. (2016) · Physiological Reviews · doi:10.1152/physrev.00041.2015 · Cited by 1,726
“Investigators have shown that the ERK-MAP kinase pathway is under control, in CFs, of miR-21 (263).”
BackgroundSelf-citationMicroRNAs in Stress Signaling and Human Disease
Mendell, J. T., & Olson, E. N. (2012) · Cell · doi:10.1016/j.cell.2012.02.005 · Cited by 1,673
“Systemic delivery of cholesterol-modified miR-21 antagomirs has been reported to diminish MAPK signaling in cardiac fibroblasts and thereby completely prevent and reverse cardiac dysfunction, fibrosis, and hypertrophy in response to pressure overload (Thum et al., 2008).”
BackgroundInfluentialTranscriptional Regulation and Its Misregulation in Disease
Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.014 · Cited by 1,620
“…disease, including arrhythmia, fibrosis, hypertrophy due to high pressure and misregulation of cardiac energy metabolism (Callis et al., 2009; Care et al., 2007; Grueter et al., 2012; Luo et al., 2008; Thum et al., 2008; van Rooij et al., 2007; van Rooij et al., 2008; Yang et al., 2007).”
Integrating mechanisms of pulmonary fibrosis
Wynn, T. A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110551 · Cited by 1,274
“In agreement with related studies (Thum et al., 2008; Kim et al., 2009b), miR-21 production was primarily localized to myofibroblasts and expression was tightly controlled by the profibrotic cytokine TGF-1 (Liu et al.”
BackgroundMicroRNA control of signal transduction
Inui, M., Martello, G., & Piccolo, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2868 · Cited by 1,272
Frangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229
MicroRNA: Function, Detection, and Bioanalysis
Dong, H., Lei, J., Ding, L., Wen, Y., Ju, H., & Zhang, X. (2013) · Chemical Reviews · doi:10.1021/cr300362f · Cited by 1,224
Pervasive roles of microRNAs in cardiovascular biology
Small, E. M., & Olson, E. N. (2011) · Nature · doi:10.1038/nature09783 · Cited by 1,180
Jansson, M. D., & Lund, A. H. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.006 · Cited by 1,099
“For example, upregulation of hypermethylated tumour suppressing miRNAs by 5-aza-20deoxycytidine treatment in the case of as miR-127 (Saito et al., 2006), miR-9-1 (Lehmann et al., 2008) and themiR-34b/c cluster (Toyota et al., 2008).”
BackgroundMicroRNAs in Development and Disease
Sayed, D., & Abdellatif, M. (2011) · Physiological Reviews · doi:10.1152/physrev.00006.2010 · Cited by 1,078
“While miR-21 is upregulated in the whole heart during pathological hypertrophy, it appears that its increase in the myofibroblasts is more significant than it is in the myocytes (612).”
BackgroundResultInfluentialTherapeutic targeting of microRNAs: current status and future challenges
Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,033
Cardiac fibroblasts: At the heart of myocardial remodeling
Porter, K. E., & Turner, N. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.05.002 · Cited by 1,010
Bang, C., Batkai, S., Dangwal, S., Gupta, S. K., Foinquinos, A., Holzmann, A., Just, A., Remke, J., Zimmer, K., Zeug, A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70577 · Cited by 979
“We previously showed, by in vitro and in vivo experiments, that miR-21 has no significant effect in cardiomyocyte hypertrophy (17).”
InfluentialSelf-citationmiR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis
Liu, G., Friggeri, A., Yang, Y., Milosevic, J., Ding, Q., Thannickal, V. J., Kaminski, N., & Abraham, E. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100035 · Cited by 935
“Aberrant expression of miRNAs is closely associated with initiation and progression of pathophysiologic processes including diabetes, cancer, and cardiovascular disease (Thum et al., 2008; Croce, 2009; Latronico and Condorelli, 2009; Pandey et al., 2009).”
BackgroundNon-coding RNAs in disease: from mechanisms to therapeutics
Nemeth, K., Bayraktar, R., Ferracin, M., & Calin, G. A. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-023-00662-1 · Cited by 885
“Silencing of miR-21 via antagomir-21 could disrupt cardiac allograft vasculopathy and prolong cardiac allograft survival 137 as well as reduce hypertrophy and fibrosis and restore impaired cardiac function 139 .”
Bernardo, B. C., Weeks, K. L., Pretorius, L., & McMullen, J. R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.005 · Cited by 894
Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities
Frangogiannis, N. G. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.07.001 · Cited by 841
The aged niche disrupts muscle stem cell quiescence
Chakkalakal, J. V., Jones, K. M., Basson, M. A., & Brack, A. S. (2012) · Nature · doi:10.1038/nature11438 · Cited by 851
“Mice carrying 1 copy of the lacZ gene encoding β -galactosidase inserted into the spry1 coding region (spry1 lacZ+/- ) was used to examine spry1 transcriptional activity 34 .”
MethodSelf-citationMicroRNA-34a regulates cardiac ageing and function.
Boon, R. A., Iekushi, K., Lechner, S., Seeger, T., Fischer, A., Heydt, S., Kaluza, D., Tréguer, K., Carmona, G., Bonauer, A., et al. (2013) · Nature · doi:10.1038/nature11919 · Cited by 821
Du, C., Liu, C., Kang, J., Zhao, G., Ye, Z., Huang, S., Li, Z., Wu, Z., & Pei, G. (2009) · Nature Immunology · doi:10.1038/ni.1798 · Cited by 811
“When poorly regulated, microRNAs are critically involved in a range of human disease”
Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease
Corsten, M. F., Dennert, R., Jochems, S., Kuznetsova, T., Devaux, Y., Hofstra, L., Wagner, D. R., Staessen, J. A., Heymans, S., & Schroen, B. (2010) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.110.957415 · Cited by 794
Ponomarev, E. D., Veremeyko, T., Barteneva, N., Krichevsky, A. M., & Weiner, H. L. (2011) · Nature Medicine · doi:10.1038/nm.2266 · Cited by 787
Mechanistic Pathways of Sex Differences in Cardiovascular Disease
Regitz-Zagrosek, V., & Kararigas, G. (2017) · Physiological Reviews · doi:10.1152/physrev.00021.2015 · Cited by 732
“miRNA-21 has already been linked to fibrosis (386).”
BackgroundAtrial Remodeling and Atrial Fibrillation
Nattel, S., & Harada, M. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.555 · Cited by 736
“miR-21 targets Sprouty 1, a negative regulator of fibroblast ERK signaling (44).”
BackgroundHeijman, J., Voigt, N., Nattel, S., & Dobrev, D. (2014) · Circulation Research · doi:10.1161/circresaha.114.302226 · Cited by 677
“MicroRNA-21 plays a major role in profibrotic remodeling by reducing Sprouty-1.(78) Sprouty-1 is a negative regulator of type 1/2 extracellular signal–related kinase, thereby inhibiting fibroblast survival and density.”
BackgroundmiRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges
Zhou, S.-S., Jin, J.-P., Wang, J.-Q., Zhang, Z.-G., Freedman, J. H., Zheng, Y., & Cai, L. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2018.30 · Cited by 675
Biological functions of microRNAs: a review
Huang, Y., Shen, X. J., Zou, Q., Wang, S. P., Tang, S. M., & Zhang, G. Z. (2011) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-010-0050-6 · Cited by 652
“These findings reveal that miRNAs can contribute to myocardial disease by their effects on cardiac fibroblasts [ 60 ].”
BackgroundShared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Frantz, S., Hundertmark, M. J., Schulz-Menger, J., Bengel, F. M., & Bauersachs, J. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac223 · Cited by 606
Self-citationMicroRNA therapeutics for cardiovascular disease: opportunities and obstacles
van Rooij, E., & Olson, E. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3864 · Cited by 624
The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy
Ucar, A., Gupta, S. K., Fiedler, J., Erikci, E., Kardasinski, M., Batkai, S., Dangwal, S., Kumarswamy, R., Bang, C., Holzmann, A., et al. (2012) · Nature Communications · doi:10.1038/ncomms2090 · Cited by 610
Self-citationFGF Receptors: Cancer Biology and Therapeutics: CANCER BIOLOGY AND THERAPEUTICS ON FGF RECEPTORS
Katoh, M., & Nakagama, H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21288 · Cited by 610
Regulation and function of miRNA-21 in health and disease
Kumarswamy, R., Volkmann, I., & Thum, T. (2011) · RNA Biology · doi:10.4161/rna.8.5.16154 · Cited by 607
Self-citationRoy, S., Khanna, S., Hussain, S.-R. A., Biswas, S., Azad, A., Rink, C., Gnyawali, S., Shilo, S., Nuovo, G. J., & Sen, C. K. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp015 · Cited by 614
“While this work was in review, two other publications have recognized the significance of miR-21 in the heart.(34,35) Changes in miR-21, specifically in CFs, can regulate heart failure.”
Junker, A., Krumbholz, M., Eisele, S., Mohan, H., Augstein, F., Bittner, R., Lassmann, H., Wekerle, H., Hohlfeld, R., & Meinl, E. (2009) · Brain · doi:10.1093/brain/awp300 · Cited by 595
“Although the quantitative impact of miRNA ‘fine tuning’ on gene expression levels is relatively small, miRNAs are nevertheless implicated in the pathogenesis of different diseases, including cancer, cardiac failure and neurodegenerative diseases (Papagiannakopoulos and Kosik, 2008; Thum et al., 2008; Hebert and De, 20…”
BackgroundMicroRNAs Add a New Dimension to Cardiovascular Disease
Small, E. M., Frost, R. J. A., & Olson, E. N. (2010) · Circulation · doi:10.1161/circulationaha.109.889048 · Cited by 599
MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways
Chau, B. N., Xin, C., Hartner, J., Ren, S., Castano, A. P., Linn, G., Li, J., Tran, P. T., Kaimal, V., Huang, X., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003205 · Cited by 587
“We, like others, found that in kidney, miR-21 also stimulates ERK/MAPK activity (5).”
BackgroundResultInfluentialHu, Y., Rao, S.-S., Wang, Z.-X., Cao, J., Tan, Y.-J., Luo, J., Li, H.-M., Zhang, W.-S., Chen, C.-Y., & Xie, H. (2018) · Theranostics · doi:10.7150/thno.21234 · Cited by 574
“Studies have demonstrated that the miR-21-dependent regulation of fibroblasts’ and endothelial cells’ activities is mediated by the activation of PI3K/Akt and ERK1/2 signaling through downregulation of PTEN and SPRY1 [19-21].”
BackgroundCardiac Fibrosis in Patients With Atrial Fibrillation
Dzeshka, M. S., Lip, G. Y. H., Snezhitskiy, V., & Shantsila, E. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.06.1313 · Cited by 552
“miR-21 is involved in up-regulation of 1 of the profibrotic pathways (ERK) and promotes MMP2 expression (36,37).”
The Promising Role of miR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics
Bautista-Sánchez, D., Arriaga-Canon, C., Pedroza-Torres, A., De La Rosa-Velázquez, I. A., González-Barrios, R., Contreras-Espinosa, L., Montiel-Manríquez, R., Castro-Hernández, C., Fragoso-Ontiveros, V., Álvarez-Gómez, R. M., et al. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.03.003 · Cited by 549
“In the case of miR-21, antimiRs offer a new therapeutic approach for liver injury(119) and cardiovascular disease.(120) In particular, mouse models with kidney injury have shown that anti-miR-21 reduced reactive oxygen species (ROS) accumulation by rescuing the expression of peroxisome proliferator-activated receptor…”
BackgroundRecent advances in the molecular pathophysiology of atrial fibrillation
Wakili, R., Voigt, N., Kääb, S., Dobrev, D., & Nattel, S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46315 · Cited by 545
van Rooij, E. (2011) · Circulation Research · doi:10.1161/circresaha.110.227496 · Cited by 534
The Extracellular Matrix in Ischemic and Nonischemic Heart Failure
Frangogiannis, N. G. (2019) · Circulation Research · doi:10.1161/circresaha.119.311148 · Cited by 520
miR-29 Is a Major Regulator of Genes Associated with Pulmonary Fibrosis
Cushing, L., Kuang, P. P., Qian, J., Shao, F., Wu, J., Little, F., Thannickal, V. J., Cardoso, W. V., & Lü, J. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0323oc · Cited by 502
“There is increasing evidence that miRNAs are key regulators of genes involved in fibrosis in organs, such as the heart (9, 10), kidney (11), and liver (12).”
BackgroundMolecular and Cellular Mechanisms of Atrial Fibrosis in Atrial Fibrillation
Nattel, S. (2017) · JACC: Clinical Electrophysiology · doi:10.1016/j.jacep.2017.03.002 · Cited by 491
“ERK pathway activation enhances fibroblast survival and promotes fibrosis (23).”
BackgroundDeveloping MicroRNA Therapeutics
van Rooij, E., Purcell, A. L., & Levin, A. A. (2012) · Circulation Research · doi:10.1161/circresaha.111.247916 · Cited by 449
Turning 21: Induction of miR-21 as a Key Switch in the Inflammatory Response
Sheedy, F. J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00019 · Cited by 496
Wong, T. C., Piehler, K., Meier, C. G., Testa, S. M., Klock, A. M., Aneizi, A. A., Shakesprere, J., Kellman, P., Shroff, S. G., Schwartzman, D. S., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.089409 · Cited by 493
MicroRNA Regulatory Networks in Cardiovascular Development
Liu, N., & Olson, E. N. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.03.010 · Cited by 491
“In this regard, modulators of miRNAs, such as antagomiRs and miR mimics, have shown promising effects on a number of cardiovascular disorders in animal models (Bonauer et al., 2009; Carè et al., 2007; Thum et al., 2008).”
BackgroundChevalier, R. L. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00164.2016 · Cited by 483
Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS
Butovsky, O., Siddiqui, S., Gabriely, G., Lanser, A. J., Dake, B., Murugaiyan, G., Doykan, C. E., Wu, P. M., Gali, R. R., Iyer, L. K., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62636 · Cited by 481
“with pathologic processes including heart disease (37), cancer (38), Alzheimer’s disease (39), and autoimmune inflammation (40).”
Microparticles: major transport vehicles for distinct microRNAs in circulation
Diehl, P., Fricke, A., Sander, L., Stamm, J., Bassler, N., Htun, N., Ziemann, M., Helbing, T., El-Osta, A., Jowett, J. B. M., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs007 · Cited by 470
Prospective Study on Circulating MicroRNAs and Risk of Myocardial Infarction
Zampetaki, A., Willeit, P., Tilling, L., Drozdov, I., Prokopi, M., Renard, J.-M., Mayr, A., Weger, S., Schett, G., Shah, A., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.056 · Cited by 464
“ator of cardiac fibrosis (34), although this is contested by others (35), and miR-24 as an inducer of endothelial apoptosis after myocardial infarction (36).”
BackgroundGiovannetti, E., Funel, N., Peters, G. J., Del Chiaro, M., Erozenci, L. A., Vasile, E., Leon, L. G., Pollina, L. E., Groen, A., Falcone, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4467 · Cited by 457
“However, no tissues from previously treated patients were available, and high levels of miR-21 may not only characterize cancers but also represent a common feature of pathologic growth or stress, as observed in models of mouse hypertrophic heart (48).”
BackgroundDeng, R., Tang, L., Tian, Q., Wang, Y., Lin, L., & Li, J. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201309388 · Cited by 450
Resveratrol and Cardiovascular Diseases
Bonnefont-Rousselot, D. (2016) · Nutrients · doi:10.3390/nu8050250 · Cited by 442
MicroRNAs in Cardiovascular Disease
Barwari, T., Joshi, A., & Mayr, M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.945 · Cited by 445
“This miRNA is increased in heart failure patients and in cardiac fibroblasts of fibrotic mouse hearts (40), and promotes ECM deposition in mouse models of increased afterload (41) and myocardial ischemia (42).”
BackgroundChemical modification and design of anti-miRNA oligonucleotides
Lennox, K. A., & Behlke, M. A. (2011) · Gene Therapy · doi:10.1038/gt.2011.100 · Cited by 433
Baggish, A. L., Hale, A., Weiner, R. B., Lewis, G. D., Systrom, D., Wang, F., Wang, T. J., & Chan, S. Y. (2011) · The Journal of Physiology · doi:10.1113/jphysiol.2011.213363 · Cited by 431
“…inflammation (miR-21, Urbich et al. 2008; Iliopoulos et al. 2010; and miR-146a, Taganov et al. 2006); skeletal and cardiac muscle function (miR-21, Thum et al. 2008; Cheng et al. 2010; and miR-133a, Chen et al. 2006; Care et al. 2007); and the cellular response to hypoxia (miR-21, Krichevsky &…”
BackgroundExtracellular matrix remodeling and cardiac fibrosis
Li, L., Zhao, Q., & Kong, W. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.013 · Cited by 419
Gomez, I. G., MacKenna, D. A., Johnson, B. G., Kaimal, V., Roach, A. M., Ren, S., Nakagawa, N., Xin, C., Newitt, R., Pandya, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci75852 · Cited by 413
“A single miRNA can silence the expression of a number of functionally related genes, and therefore, miRNA can function in an analogous but reciprocal way to transcription factors (2, 3).”
Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives
Poller, W., Dimmeler, S., Heymans, S., Zeller, T., Haas, J., Karakas, M., Leistner, D.-M., Jakob, P., Nakagawa, S., Blankenberg, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx165 · Cited by 408
“Inhibition of miR21 prevented HF development in mice.(40) MicroRNAs also regulate intracellular calcium homeostasis, a process that is strongly deregulated during HF, thereby directly affecting cardiac contractility.”
BackgroundSelf-citationSmad3-Mediated Upregulation of miR-21 Promotes Renal Fibrosis
Zhong, X., Chung, A. C. K., Chen, H.-Y., Meng, X.-M., & Lan, H. Y. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111168 · Cited by 409
Stanczyk, J., Ospelt, C., Karouzakis, E., Filer, A., Raza, K., Kolling, C., Gay, R., Buckley, C. D., Tak, P. P., Gay, S., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30115 · Cited by 407
“Given recent reports of successful approaches to targeting miRNA in vivo (39-41), our data suggest that miR-203 may be a new therapeutic target in RA.”
BackgroundFibroblasts in the Infarcted, Remodeling, and Failing Heart
Humeres, C., & Frangogiannis, N. G. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.02.006 · Cited by 410
“MiR-21 is markedly induced in infarct fibroblasts (129) and may exert fibrogenic actions by stimulating MAPK activation in cardiac fibroblasts (130) or by targeting the TGF-b cascade (131).”
BackgroundAurora, A. B., Mahmoud, A. I., Luo, X., Johnson, B. A., van Rooij, E., Matsuzaki, S., Humphries, K. M., Hill, J. A., Bassel-Duby, R., Sadek, H. A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59327 · Cited by 404
“…ʹ -UTRs of target mRNAs that have complementarity to nucleotides 2–8 of the miRNA, known as the seed region. miRNAs mediate numerous cellular processes associated with cardiac remodeling and disease, including myocyte hypertrophy (3–9), fibrosis (10–13), angiogenesis (14–16), and apoptosis (17–21).”
Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart
Creemers, E. E., & Pinto, Y. M. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvq308 · Cited by 403
“2 miR-21 A recent study by Thum et al.(80) has identified miR-21 as a disease target in heart failure.”
InfluentialDiagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome
Widera, C., Gupta, S. K., Lorenzen, J. M., Bang, C., Bauersachs, J., Bethmann, K., Kempf, T., Wollert, K. C., & Thum, T. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.07.011 · Cited by 397
“MiRNAs are involved in various pathological conditions including cardiovascular disease [2–4], and tissue expression levels of several miRNAs are altered in the heart in response to pathological stress [5].”
BackgroundSelf-citationMicroRNA-24 Regulates Vascularity After Myocardial Infarction
Fiedler, J., Jazbutyte, V., Kirchmaier, B. C., Gupta, S. K., Lorenzen, J., Hartmann, D., Galuppo, P., Kneitz, S., Pena, J. T. G., Sohn-Lee, C., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.039008 · Cited by 393
Self-citationCardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload
Takeda, N., Manabe, I., Uchino, Y., Eguchi, K., Matsumoto, S., Nishimura, S., Shindo, T., Sano, M., Otsu, K., Snider, P., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40295 · Cited by 389
“And very recently it was shown that inhibition of a fibroblast-selective miRNA ameliorated cardiac fibrosis, hypertrophy, and dysfunction, suggesting that fibroblasts play a detrimental role in cardiac remodeling (12).”
BackgroundLong Noncoding RNAs and MicroRNAs in Cardiovascular Pathophysiology
Thum, T., & Condorelli, G. (2015) · Circulation Research · doi:10.1161/circresaha.116.303549 · Cited by 385
“shown to silence the ERK–MAP kinase inhibitor sprouty-1, which is mechanistically involved in fibrosis development.(36)”
BackgroundSelf-citationStability of Circulating Blood-Based MicroRNAs – Pre-Analytic Methodological Considerations
Glinge, C., Clauss, S., Boddum, K., Jabbari, R., Jabbari, J., Risgaard, B., Tomsits, P., Hildebrand, B., Kääb, S., Wakili, R., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0167969 · Cited by 351
microRNAs in Cardiovascular Diseases
Condorelli, G., Latronico, M. V. G., & Cavarretta, E. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.050 · Cited by 375
“cardiac function in response to pressure overload (28)”
BackgroundApoptosis and the target genes of microRNA-21
Buscaglia, L. E. B., & Li, Y. (2011) · Chinese Journal of Cancer · doi:10.5732/cjc.011.10132 · Cited by 378
Segura, A. M., Frazier, O. H., & Buja, L. M. (2014) · Heart Failure Reviews · doi:10.1007/s10741-012-9365-4 · Cited by 371
Identification of a microRNA signature of renal ischemia reperfusion injury
Godwin, J. G., Ge, X., Stephan, K., Jurisch, A., Tullius, S. G., & Iacomini, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912701107 · Cited by 373
“Moreover, miR21 expression has been linked to fibrosis (14), a major complication resulting from renal IRI in which TGF-β plays a central role (26).”
BackgroundInfluentialDiffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches
López, B., Ravassa, S., Moreno, M. U., José, G. S., Beaumont, J., González, A., & Díez, J. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00504-1 · Cited by 361
MicroRNA-21 protects against the H2O2-induced injury on cardiac myocytes via its target gene PDCD4
Cheng, Y., Liu, X., Zhang, S., Lin, Y., Yang, J., & Zhang, C. (2009) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2009.01.008 · Cited by 368
“, they have also found that downregulation of miR21 in adult heart by an antagomir approach is able to reduce interstitial fibrosis, cardiomyocyte size and the heart weight under the hypertrophy-inducing condition [28].”
BackgroundStress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice
Patrick, D. M., Montgomery, R. L., Qi, X., Obad, S., Kauppinen, S., Hill, J. A., van Rooij, E., & Olson, E. N. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43604 · Cited by 360
“However, Western blot analysis showed a stress-dependent increase in phospho-Erk even in the absence of miR-21 (Figure 2B).”
BackgroundInfluentialmiR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes
Zhong, X., Chung, A. C. K., Chen, H. Y., Dong, Y., Meng, X. M., Li, R., Yang, W., Hou, F. F., & Lan, H. Y. (2013) · Diabetologia · doi:10.1007/s00125-012-2804-x · Cited by 355
“These results are consistent with the pathological role of miR-21 in cardiac, lung and renal fibrosis [7, 22, 26].”
BackgroundResultShea, K. L., Xiang, W., LaPorta, V. S., Licht, J. D., Keller, C., Basson, M. A., & Brack, A. S. (2010) · Cell stem cell · doi:10.1016/j.stem.2009.12.015 · Cited by 351
“To characterize Spry1 expression in muscle on a cell-by-cell basis, we analyzed mice carrying one copy of a Spry1lacZ knockin allele (Spry1lacZ/+) (Thum et al., 2008) as a readout of Spry1 expression.”
BackgroundSelf-citationMicroRNA control of muscle development and disease
Williams, A. H., Liu, N., van Rooij, E., & Olson, E. N. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.029 · Cited by 350
Bollati, V., Marinelli, B., Apostoli, P., Bonzini, M., Nordio, F., Hoxha, M., Pegoraro, V., Motta, V., Tarantini, L., Cantone, L., et al. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.0901300 · Cited by 347
Lu, T. X., Hartner, J., Lim, E.-J., Fabry, V., Mingler, M. K., Cole, E. T., Orkin, S. H., Aronow, B. J., & Rothenberg, M. E. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101235 · Cited by 341
“This is illustrated in part by the recent report that miR-21–deficient mice have no alteration in cardiac remodeling, even though this outcome was expected based on predictive algorithms and antagomir studies (21, 30).”
BackgroundMicroRNA-21 preserves the fibrotic mechanical memory of mesenchymal stem cells
Li, C. X., Talele, N. P., Boo, S., Koehler, A., Knee-Walden, E., Balestrini, J. L., Speight, P., Kapus, A., & Hinz, B. (2017) · Nature Materials · doi:10.1038/nmat4780 · Cited by 336
MicroRNA-21 in Cardiovascular Disease
Cheng, Y., & Zhang, C. (2010) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-010-9169-7 · Cited by 334
“reported that miR-21 was not highly expressed in cardiac myocytes [29].”
BackgroundInfluentialAdult-specific functions of animal microRNAs
Sun, K., & Lai, E. C. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3471 · Cited by 334
RNA-based diagnostic and therapeutic strategies for cardiovascular disease
Lu, D., & Thum, T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0218-x · Cited by 331
Self-citationMicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism
Lu, H., Buchan, R. J., & Cook, S. A. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq010 · Cited by 334
Jansen, F., Yang, X., Proebsting, S., Hoelscher, M., Przybilla, D., Baumann, K., Schmitz, T., Dolf, A., Endl, E., Franklin, B. S., et al. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001249 · Cited by 330
Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease
Gourdie, R. G., Dimmeler, S., & Kohl, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.89 · Cited by 332
Akhtar, N., Rasheed, Z., Ramamurthy, S., Anbazhagan, A. N., Voss, F. R., & Haqqi, T. M. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27329 · Cited by 331
“Furthermore, the role of MAPKs in regulating microRNA expression in cardiac disease has recently been proposed (49).”
Developing Therapies for Heart Failure With Preserved Ejection Fraction
Butler, J., Fonarow, G. C., Zile, M. R., Lam, C. S., Roessig, L., Schelbert, E. B., Shah, S. J., Ahmed, A., Bonow, R. O., Cleland, J. G. F., et al. (2014) · JACC: Heart Failure · doi:10.1016/j.jchf.2013.10.006 · Cited by 324
“Experimental models have produced HF by creating diffuse fibrosis from cardiac fibroblast activation (50) suggesting a primary role for fibroblast activity.”
BackgroundRoncarati, R., Viviani Anselmi, C., Losi, M. A., Papa, L., Cavarretta, E., Da Costa Martins, P., Contaldi, C., Saccani Jotti, G., Franzone, A., Galastri, L., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.041 · Cited by 327
“We also found that in contrast with miR-29a, another miRNA involved in cardiac fibrosis, miR-21 (39), although also significantly increased in HCM plasma, did not correlate with the degree of hypertrophy or with the extension of myocardial fibrosis.”
Resultda Costa Martins, P. A., Salic, K., Gladka, M. M., Armand, A.-S., Leptidis, S., el Azzouzi, H., Hansen, A., Coenen-de Roo, C. J., Bierhuizen, M. F., van der Nagel, R., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2126 · Cited by 323
miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes
Qian, L., Van Laake, L. W., Huang, Y., Liu, S., Wendland, M. F., & Srivastava, D. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101547 · Cited by 322
MicroRNA let-7c Regulates Macrophage Polarization
Banerjee, S., Xie, N., Cui, H., Tan, Z., Yang, S., Icyuz, M., Abraham, E., & Liu, G. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202496 · Cited by 320
Metadata
- Authors
- Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., Castoldi, M., Soutschek, J., Koteliansky, V., Rosenwald, A., Basson, M. A., Licht, J. D., Pena, J. T. R., Rouhanifard, S. H., Muckenthaler, M. U., Tuschl, T., Martin, G. R., Bauersachs, J., & Engelhardt, S.
- Affiliations
- University of Würzburg (DE)
- Deutsche Forschungsgemeinschaft (DE)
- University of California, San Francisco (US)
- Heidelberg University (DE)
- Regulus Therapeutics (United States) (US)
- Alnylam Pharmaceuticals (United States) (US)
- King's College London (GB)
- Northwestern University (US)
- Rockefeller University (US)
- Technical University of Munich (DE)
- Corresponding author
- Bauersachs, Johann
- Engelhardt, Stefan
- ORCID
- Thum, Thomas
- Gross, Carina
- Fiedler, Jan
- Fischer, Thomas
- Kissler, Stephan
- Galuppo, Paolo
- Just, Steffen
- Rottbauer, Wolfgang
- Frantz, Stefan
- Castoldi, Mirco
- Rosenwald, Andreas
- Basson, M. Albert
- Licht, Jonathan D.
- Pena, John T. R.
- Rouhanifard, Sara H.
- Muckenthaler, Martina U.
- Tuschl, Thomas
- Bauersachs, Johann
- Engelhardt, Stefan
- Venue
- Nature
- Published
- 2008-11-30
- Volume
- 456
- Issue
- 7224
- Pages
- 980-984
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2132093971
- Cited by
- 2,349
- References
- 30
- Citations by year
- 2026: 62 · 2025: 70 · 2024: 71 · 2023: 76 · 2022: 106 · 2021: 131 · 2020: 151 · 2019: 138 · 2018: 153 · 2017: 167 · 2016: 150 · 2015: 200 · 2014: 183 · 2013: 203 · 2012: 176
- FWCI
- 75.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- National Cancer Institute (R01CA078711, R01 CA 78711, R01CA059998)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- miR-21, cardiac fibroblasts, heart failure, SPRY1, interstitial fibrosis, cardiac hypertrophy, microRNA silencing, antagomir, fibroblast survival, therapeutic target, cardiomyocytes
- MeSH terms
- Animals, Cell Line, Cell Survival, Cells, Cultured, Disease Models, Animal, Fibroblasts, Humans, Male, Mice, Transgenic, Cardiomyopathies, Gene Silencing, MAP Kinase Signaling System, Myocytes, Cardiac, MicroRNAs, Extracellular Signal-Regulated MAP Kinases, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.